Barclays Capital disclosed Hikma Pharmaceuticals PLC (LON:HIK), supporting its stock price target at 2,800.00GBX earlier today
- Updated: September 18, 2016
Having a price of 0.00GBX, Hikma Pharmaceuticals PLC (LON:HIK) traded 0.80% lower on the day. With the last stock close down 4.75% relative to the 200-day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. HIK has recorded a 50-day average of 2,273.76GBX and 200-day moving average of 2,221.42GBX. Volume of trade was was down over the average, with 508,620 shares of HIK changing hands under the typical 581,547 shares.
Hikma Pharmaceuticals PLC (LON:HIK) had its price target maintained to 2,800GBX by Barclays Capital in a report released 8/04/2016. The target price indicates a potential improbable upside the company’s most recent closing price.
Previously on 7/26/2016, Jefferies released a statement for Hikma Pharmaceuticals PLC(LON:HIK) raised the target price from 2,800.00GBX to 2,990.00GBX. At the time, this suggested an upside of 0.13%.
Recent Performance Graphic:
Also covering Hikma Pharmaceuticals PLC’s stock price target, a total of 9 brokerages have reported on HIK. The one year target stock price is 32.71GBX with four firms rating the stock a strong buy, six analysts rating the company a buy, 0 firms rating the stock a hold, 0 rating the company to underperform, and lastly 0 firms rating the company as sell.
Hikma Pharmaceuticals PLC has a one-year low of 1,575.00GBX and a 52 week high of 2,703.00GBX with a P/E ratio of 26 and has a market capitalization of 0.0 GBX.
General Company Details For Hikma Pharmaceuticals PLC (LON:HIK)
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company’s segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1, 120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business’ products include Argatroban, Fentanyl, Glycopyrrolate, and Nicardipine and Phenylephrine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.